Recently, Fan Xiude, a doctoral student supervised by Professor Liu Zhengwen from the First Affiliated Hospital of Xi’an Jiaotong University (XJTU), as the first author published two articles entitled "Diagnostic and Prognostic Significance of Complement in Patients with Alcohol-associated Hepatitis" and "Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score Matched Study using UK Biobank” in Hepatology (IF=14.679) and Gastroenterology (IF=17.373), respectively. In December 2018, Fan Xiude studied in Cleveland Medical Center in the United States under the support of Joint Doctoral Training Project of China Scholarship Council, and successfully completed the research of relevant projects jointly supervised by Professor Liu Zhengwen and Professor Laura Nagy from Cleveland Medical Center.
In the article published in Hepatology, it is found that the classical signaling pathway and lectin signaling pathway of complement may be inhibited in patients with alcohol-associated hepatitis, whereas the alternative signaling pathway is enhanced instead. Furthermore, complement factor I (CFI) and soluble terminal complement complex (sC5b9) in the plasma can be utilized as efficient biomarkers for the diagnosis and prognosis of alcohol-associated hepatitis. To further evaluate the clinical prognosis of patients with alcohol-associated hepatitis, the MELD-Complement score prognostic evaluation model was established based on CFI and sC5b9 in combination with age, albumin and MELD score. Compared with traditional prognostic prediction model, the prediction efficiency for 90-d death risk of patients with severe alcohol-associated hepatitis was significantly improved.
During the outbreak of COVID-19 pandemic, Fan Xiude, as a doctoral student in Department of Infectious Diseases and supervised by Professor Liu Zhengwen, an infectious disease expert, focused on whether the use of current acid inhibitors could increase the risk of COVID-19 infection and death. By analyzing international database and literature review, it is found that the use of proton pump inhibitors and histamine 2 receptor antagonists does not increase the risk of COVID-19 infection and death, whereas patients with the upper gastrointestinal diseases treated with omeprazole are more prone toCOVID-19. The above findings provide guidance for clinicians to formulate acid-suppression regimes for patients with the upper gastrointestinal diseases during the COVID-19 pandemic. The findings of this study were published in Gastroenterology.
In 2017, Fan Xiude was admitted to our hospital to advance study for a doctor's degree in internal medicine. He has published 33 articles in SCI-indexed journals, including 9 articles as the first or co-first author.
Article link:https://www.researchgate.net/profile/Xiude_Fan
